课题基金 / 基金详情

项目摘要

项目成果

DAVID M KENT的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):超过三分之一的中风是“隐源性”的;尽管进行了测试,但病因不明。隐源性卒中(CS)患者卵圆孔未闭(PFO)的患病率约为50%,而在一般人群中仅为25%。这表明矛盾栓塞(PE),静脉栓塞通过PFO进入动脉循环,是CS的主要原因。许多医生建议关闭PFO,特别是对年轻患者,但手术的好处尚未得到证实。对于患有CS和PFO的患者,尚不清楚PFO是否与卒中有因果关系或偶发,并且CS和PFO患者卒中复发罕见(研究的平均年化风险约为2%)。虽然某些人的风险高于平均水平(例如房间隔动脉瘤患者),但其他人的风险也必须低于平均水平。如何确定中风是由PE引起的,如何预测个体的复发风险尚不清楚。先前的研究受到
英文摘要
DESCRIPTION (provided by applicant): Over one-third of all strokes are "cryptogenic"; their cause is unknown despite testing. The prevalence of patent foramen ovale (PFO) in patients with cryptogenic stroke (CS) is ~50%, yet only 25% in the general population. This suggests that paradoxical embolism (PE), venous emboli that access the arterial circulation via a PFO, is a major cause of CS. Many doctors advise PFO closure, especially for young patients, but the procedure's benefit is unproven. For someone with CS and PFO, it is not clear for that person if the PFO is causally related to the stroke or incidental, and stroke recurrence is uncommon in patients with CS and PFO (average annualized risk across studies is ~2%). While the risk is above average for some (e.g. those with atrial septal aneurysm), it must also be below average in others. How to determine that the stroke was caused by PE and how to predict recurrence risk for individuals is not known. Prior studies have been limited by extremely low statistical power for examining factors related to recurrence and have contradictory and even paradoxical findings, likely due to confounding stroke risk from other causes, which were not properly controlled for. In order to advise patients about the potential benefits of therapy, needed is a means of predicting, in the individual patient, the likelihood that the PFO was causal rather than incidental to the index event and the probability that such an event will recur. The goals of the Risk of Paradoxical Embolism (ROPE) Study are to identify: 1) patients at high risk for recurrent stroke from PE (not just recurrent stroke in general) who can be helped with PFO closure, and 2) patients who are at low risk of recurrence of PE (incidental PFO or benign natural history) who are unlikely to benefit from closure. We hypothesize that patient characteristics in those with CS (with and without PFO) can be used to identify those in whom a discovered PFO is more or less likely to be causally related to the stroke. Further, we hypothesize that, in patients with CS and PFO, the risk of stroke recurrence, and specifically recurrence from PE, is predictable from clinical, radiologic and echocardiographic variables available at the time of the index stroke. Thus, the specific aims of the ROPE Study are: 1) To build the largest database of CS using existing cohort studies of patients with CS studied with TEE, both with and without PFO, sufficiently robust to support predictive risk modeling; 2. To identify, CS patients, patient characteristics that are associated with the presence (versus the absence) of a PFO; 3) To develop, among patients with both a CS and a PFO, a predictive model to estimate patient-specific stroke recurrence risk based on clinical, radiographic and echocardiographic characteristics; 4) To develop an index based on these models that can stratify patients with CS and PFO by their conditional probability that the PFO was causally-related to the index stroke and the risk of stroke recurrence; 5) To apply this score to stratify patients in clinical trials testing endovascular PFO closure against medical therapy, from low-expected-benefit to high-expected-benefit, and to test for a treatment-effect-by-strata interaction. PUBLIC HEALTH RELEVANCE One out of every four people in the general population have a small hole in their heart known as a patent foramen ovale (PFO) but in patients with stroke, many of whom are young and with no explanation for why they should have had a stroke, these holes are found in around one in two people. In these patients, no one knows how to tell if the PFO allowed a blood clot to pass through it and cause a stroke or if it is an innocent bystander and the stroke was caused by something else and many doctors argue that all such holes should be closed, using new non-surgical methods, rather than just blood thinning pills. By examining the largest collection of patients ever assembled for this problem, the ROPE Study team aims to identify the patients who should have their PFO closed in order to prevent another stroke and equally importantly to identify those for whom PFO-closure would not be likely to help and may even lead to harm.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CTSA Predoctoral T32 at Tufts University
  • 批准号:
    10621977
  • 项目类别:
  • 资助金额:
    $54.35万
  • 财政年份:
    2023
  • 负责人:
    DAVID M KENT
  • 依托单位:
Covert Cerebrovascular Disease Detected by Artificial Intelligence (C2D2AI): A Platform for Pragmatic Evidence Generation for Stroke and Dementia Prevention
  • 批准号:
    10591063
  • 项目类别:
  • 资助金额:
    $289.48万
  • 财政年份:
    2023
  • 负责人:
    DAVID M KENT
  • 依托单位:
CTSA Postdoctoral T32 at Tufts University
  • 批准号:
    10621976
  • 项目类别:
  • 资助金额:
    $52.15万
  • 财政年份:
    2023
  • 负责人:
    DAVID M KENT
  • 依托单位:
CTSA Graduate Program
  • 批准号:
    10396575
  • 项目类别:
  • 资助金额:
    $91.99万
  • 财政年份:
    2018
  • 负责人:
    DAVID M KENT
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: